Key Points These two healthcare stocks are top names to invest in, but they haven’t both been doing well of late. Eli Lilly has generated

When HCA Healthcare, one of the largest hospital systems in the U.S., recently told employees it would stop covering blockbuster obesity drugs Zepbound and Wegovy

A growing body of evidence suggests GLP-1 receptor agonists may improve survival as well as reduce chemotherapy-related toxicities in women with breast cancer. Medscape Medical

IJMS, Vol. 26, Pages 12163: GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review International Journal of Molecular Sciences doi: 10.3390/ijms262412163 Authors:

submitted by /u/Accurate_Cry_8937 [link] [comments]

SAN FRANCISCO and SUZHOU, China, Dec. 17, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes

(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) in patients with type

What You Should Know:  – Weight Watchers has unveiled a massive platform overhaul integrating GLP-1 prescription management with a redesigned app featuring an AI body

Anna Sinaiko. Stephanie Mitchell/Harvard Staff Photographer Health Is cost curbing use of weight loss drugs? 40 percent of GLP-1 prescriptions go unfilled, study finds Alvin

Post Content

WEDNESDAY, Dec. 17, 2025 — Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect against vertebral fractures in people with diabetes, according to a research

Vivian Ho and Salpy Kanimian in The Conversation: Some of the premium increases can be attributed to an increase in hospital outpatient visits and coverage of GLP-1 drugs.

IJMS, Vol. 26, Pages 12149: Molecular Mechanisms and Antidiabetic Effects of Mango (Mangifera indica) Leaf Extract as a GLP-1 Analogue in Type 2 Diabetic Rats

ATLANTA — The use of GLP-1 drugs to treat obesity has cause awareness of the complex medical condition to surge. But the cost of treating

GLP-1 RA and SGLT2i have demonstrated cardio-renal protective effects in randomized clinical trials. However, their comparative cardio-renal benefits in diabetes patients with stage 4–5 chronic

SAN MATEO, Calif.–(BUSINESS WIRE)–Evidation, the leader in direct-from-participant real-world data and health research, is announcing new preliminary insights suggesting that nearly 1 in 7 injectable

SALT LAKE CITY, Dec. 17, 2025 /PRNewswire/ — Shed, the wellness brand known for health and weight-loss solutions, has launched three new products to support

IJMS, Vol. 26, Pages 12130: The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition International Journal of Molecular Sciences

Cells, Vol. 14, Pages 2009: Liraglutide-Driven Weight Loss Modulates Placental Remodeling in Obese Pregnancies in Mice Cells doi: 10.3390/cells14242009 Authors: Natassia Rodrigo Dunja Aksentijevic Nikayla

In this episode of Raising America, Elizabeth Prann sits down with Director of the National Center for Weight and Wellness, Scott Kahan. He is a

(MedPage Today) — As part of a longevity push, telehealth company Noom is now offering microdoses of GLP-1 receptor agonists outside the labels’ indications, including

Pharmaceuticals, Vol. 18, Pages 1896: Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process Pharmaceuticals doi: 10.3390/ph18121896 Authors:

Plus, news about: Hansoh, Caris-Genentech, Royalty, LIB, Greenwich LifeSciences, Gubra, J&J, Sprout, Tiziana and Vor. 💊 OrsoBio’s early obesity data: When combined with Lilly’s tirzepatide,

Exciting new findings indicate that GLP-1 weight-loss medications might dramatically reduce the likelihood of 10 types of cancer linked to obesity for patients with type

BOSTON–(BUSINESS WIRE)–Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access

From cereal and granola to snacks and soda, Big Chalk’s Fall 2025 report outlines where GLP-1 users are cutting back – and what brands should

Rise and shine, another busy day is on the way. We can tell because the official mascots got an early start chasing down cats, squirrels,

Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies

Abstract Aims Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once-weekly dosing that supports adherence. However,

A live broadcast of President Lee Jae Myung delivering a policy briefing to the Ministry of Health and Welfare airs on televisions in the main

Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as the biopharmaceutical firm positions itself as

Brooks Nader was surprised to see an outpouring of support from women from all walks of life after she opened up about her addiction to

MONDAY, Dec. 15, 2025 — For adults with type 2 diabetes mellitus (T2DM), glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy is associated with a reduced

Post Content

What You Should Know:  – Noom has launched Proactive Health Microdose GLP-1Rx, a first-of-its-kind preventive health program designed to intervene before chronic disease takes root. 

What You Should Know:  – The Peterson Health Technology Institute (PHTI) has released a critical purchasing guide for employers struggling to manage the skyrocketing costs

submitted by /u/ranjitsingh7 [link] [comments]

Destination XL Group (DXL) and FullBeauty Brands, both giants in the big-and-tall/inclusive-sizing category, will combine in a “merger of equals” with combined net sales of

From shifting grocery habits to new product opportunities, Circana’s insights reveal how brands and retailers can adapt to the rise of GLP-1 users.

Wasatch Global Investors, an asset management company, released its third-quarter 2025 “Wasatch Small Cap Growth Strategy” investor letter. A copy of the letter can be